A new mindset for combination product development
In this article, Asmita Khanolkar, Senior Director, Cambridge Pharma, at SMC, outlines the latest trends in combination product development to overcome some of the current challenges of high dose/viscosity/volume delivery.
Based on the learnings from the covid-19 pandemic, it is time to emphasise the changing mindset towards a forward- looking design and development process for combination products. The new outlook for the pharmaceutical industry is very different from the one we knew prior to the pandemic. The new normal encompasses rapid development of treatments and new regulatory pathways to support the urgency towards faster times to clinic.
Treatments are now administered outside traditional hospital care settings, including clinical studies conducted at home. We have seen a dramatic shift from a one-size-fits-all approach towards rising personalised medicine. Novel therapies considered too complex and complicated previously are now available in the hands of patients, and there is an unmet need for enabling device technology that can handle the challenging formulations. Finally, global digital transformation is modernising the overall healthcare experience.
No comments were found for A new mindset for combination product development. Be the first to comment!